Poly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy

Biomaterials

Volumn 35, Issue 27, 2014, Pages 7992-8001

  Seth, Anushree ^a   Heo, Min Beom ^a   Lim, Yong Taik ^b  

^a Chungnam National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Chemotherapy; Combination therapy; Drug delivery; Immuno stimulation; Poly( glutamic acid)

Indexed keywords

AMINO ACIDS; ANTIGENS; CELL CULTURE; CHEMICAL ACTIVATION; CHEMOTHERAPY; DISEASES; DRUG DELIVERY; FUNCTIONAL POLYMERS; MAMMALS;

ANTIGEN PRESENTING CELLS; COMBINATION THERAPY; GLUTAMIC ACID; IMMUNO-STIMULATION; INDIVIDUAL COMPONENTS; INHIBITION OF TUMOR GROWTH; THERAPEUTIC AGENTS; WATERSOLUBLE POLYMERS;

TUMORS;

IMIQUIMOD; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; PACLITAXEL; POLY(GAMMA GLUTAMIC ACID); POLYMER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WATER; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; POLY(GAMMA-GLUTAMIC ACID); POLYGLUTAMIC ACID; TOLL LIKE RECEPTOR 7;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DISPERSION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNE RESPONSE; LYMPH NODE; MACROPHAGE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEDIMENTATION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR MICROENVIRONMENT; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; PARTICLE SIZE; PATHOLOGY; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; SURVIVAL; TUMOR CELL LINE; TUMOR VOLUME;

AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; DENDRITIC CELLS; FEMALE; HUMANS; LYMPH NODES; MACROPHAGES; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, SCANNING; PACLITAXEL; PARTICLE SIZE; POLYGLUTAMIC ACID; SOLUBILITY; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 7; TUMOR BURDEN; WATER;

EID: 84903486599     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.076     Document Type: Article

References (52)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA: A Cancer J Clin 2013, 63(1):11-30.
2. Junttila M.R., de Sauvage F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501(7467):346-354.
3. Egeblad M., Nakasone E.S., Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010, 18(6):884-901.
4. Love R.R., Leventhal H., Easterling D.V., Nerenz D.R. Side effects and emotional distress during cancer chemotherapy. Cancer 1989, 63(3):604-612.
5. Rowinsky E.K., Donehower R.C. Paclitaxel (Taxol). New Engl J Med 1995, 332(15):1004-1014.
6. Marupudi N.I., Han J.E., Li K.W., Renard V.M., Tyler B.M., Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007, 6(5):609-621.
7. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235(1-2):179-192.
8. Elstad N.L., Fowers K.D. OncoGel (ReGel/paclitaxel) - Clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev 2009, 61(10):785-794.
9. Singh S., Dash A.K. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. Crit Rev Ther Drug Carrier Syst 2009, 26(4):333-372.
10. Chow L.W., Xu B., Gupta S., Freyman A., Zhao Y., Abbas R., et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer 2013, 108(10). 1985-1993.
11. Trail P.A., Willner D., Bianchi A.B., Henderson A.J., TrailSmith M.D., Girit E., et al. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin. Clin Cancer Res 1999, 5(11):3632-3638.
12. Holmes F.A. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review. Semin Oncol 1996, 23(5 Suppl.11):46-56.
13. Smorenburg C.H., Sparreboom A., Bontenbal M., Verweij J. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. Eur J Cancer 2001, 37(18):2310-2323.
14. Mapara M.Y., Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. JClin Oncol 2004, 22(6):1136-1151.
15. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10(9):909-915.
16. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 2001, 411(6835):380-384.
17. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy 2009, 1(6):949-964.
18. Schön M.P., Schön M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008, 27(2):190-199.
19. Dunne A., Marshall N.A., Mills K.H.G. TLR based therapeutics. Curr Opin Pharmacol 2011, 11(4):404-411.
20. Huang Z., Yang Y., Jiang Y., Shao J., Sun X., Chen J., et al. Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers. Biomaterials 2013, 34(3):746-755.
21. Marabelle A., Kohrt H., Levy R. Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res 2013, 19(19):5261-5263.
22. Houot R., Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009, 113(15):3546-3552.
23. Stone G.W., Barzee S., Snarsky V., Santucci C., Tran B., Langer R., et al. Nanoparticle-delivered multimeric soluble CD40L DNA combined with toll-like receptor agonists as a treatment for melanoma. PLoS One 2009, 4(10):e7334.
24. Yu L., Wang L., Chen S. Dual character of toll-like receptor signaling: pro-tumorigenic effects and anti-tumor functions. Biochim Biophys Acta -Rev Cancer 2013, 1835(2):144-154.
25. Vidal D., Alomar A. Mode of action and clinical use of imiquimod. Expert Rev Dermatol 2008, 3(2):151-159.
26. Vacchelli E., Galluzzi L., Eggermont A., Fridman W.H., Galon J., Sautès-Fridman C., et al. Trial watch FDA-approved toll-like receptor agonists for cancer therapy. Oncoimmunology 2012, 1(6):894-907.
27. Ambach A., Bonnekoh B., Nguyen M., Schön M.P., Gollnick H. Imiquimod. a toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes invitro. Mol Immunol 2004, 40(18):1307-1314.
28. Redondo P., del Olmo J., López-Diaz de Cerio A., Inoges S., Marquina M., Melero I., et al. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. JInvest Dermatol 2007, 127(7):1673-1680.
29. Witt P.L., Ritch P.S., Reding D., McAuliffe T.L., Westrick L., Grossberg S.E., et al. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 1993, 53(21):5176-5180.
30. Kaczanowska S., Joseph A.M., Davila E. TLR agonists: our best frenemy in cancer immunotherapy. JLeukoc Biol 2013, 93(6):847-863.
31. Galluzzi L., Vacchelli E., Eggermont A., Fridman W.H., Galon J., Sautès-Fridman C., et al. Trial watch experimental toll-like receptor agonists for cancer therapy. Oncoimmunology 2012, 1(5):699-716.
32. Adams M., Navabi H., Croston D., Coleman S., Tabi Z., Clayton A., et al. The rationale for combined chemo/immunotherapy using a toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 2005, 23(17-18):2374-2378.
33. Jeung H.C., Moon Y.W., Rha S.Y., Yoo N.C., Roh J.K., Noh S.H., et al. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A: U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol 2008, 19(3):520-526.
34. Roy A., Singh M.S., Upadhyay P., Bhaskar S. Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response at the tumor microenvironment in a mouse model. Int J Pharm 2013, 445(1-2):171-180.
35. Kohlmeyer J., Cron M., Landsberg J., Bald T., Renn M., Mikus S., et al. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res 2009, 69(15):6265-6274.
36. Kim J.H., Noh Y.W., Heo M.B., Cho M.Y., Lim Y.T. Multifunctional hybrid nanoconjugates for efficient invivo delivery of immunomodulating oligonucleotides and enhanced antitumor immunity. Angew Chem Int Ed Engl 2012, 51(38):9670-9673.
37. John J., Ismail M., Riley C., Askham J., Morgan R., Melcher A., et al. Differential effects of paclitaxel on dendritic cell function. Bmc Immunol 2010, 11:14.
38. Muenchen H.J., Lin D.L., Walsh M.A., Keller E.T., Pienta K.J. Tumor necrosis factor-α-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-κb by an iκbα "super-repressor". Clin Cancer Res 2000, 6(5). 1969-1977.
39. Pfannenstiel L.W., Lam S.S., Emens L.A., Jaffee E.M., Armstrong T.D. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol 2010, 263(1):79-87.
40. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002, 3(2):196-200.
41. Rabinow B.E. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004, 3(9):785-796.
42. Bhakay A., Merwade M., Bilgili E., Dave R.N. Novel aspects of wet milling for the production of microsuspensions and nanosuspensions of poorly water-soluble drugs. Drug Dev Ind Pharm 2011, 37(8):963-976.
43. Serajuddin A.T. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. JPharm Sci 1999, 88(10):1058-1066.
44. Tho I., Liepold B., Rosenberg J., Maegerlein M., Brandl M., Fricker G. Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media. Eur J Pharm Sci 2010, 40(1):25-32.
45. Kono H., Rock K.L. How dying cells alert the immune system to danger. Nat Rev Immunol 2008, 8(4):279-289.
46. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. JLeukoc Biol 2007, 81(1):1-5.
47. Lotze M.T., Zeh H.J., Rubartelli A., Sparvero L.J., Amoscato A.A., Washburn N.R., et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007, 220(1):60-81.
48. Stary G., Bangert C., Tauber M., Strohal R., Kopp T., Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. JExp Med 2007, 204(6):1441-1451.
49. Ataera H., Hyde E., Price K.M., Stoitzner P., Ronchese F. Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS One 2011, 6(3). e17515.
50. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004, 4(12):941-952.
51. Norian L.A., Rodriguez P.C., O'Mara L.A., Zabaleta J., Ochoa A.C., Cella M., et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via l-arginine metabolism. Cancer Res 2009, 69(7):3086-3094.
52. Dhodapkar M.V., Dhodapkar K.M., Palucka A.K. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ 2007, 15(1):39-50.